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Schizophrenia is a chronic and severe mental disorder characterized by positive, negative,
and cognitive symptoms. Negative symptoms are usually present from the prodromal
phase; early diagnosis and management of negative symptoms is a major health concern
since an insidious onset dominated by negative symptoms is associated with a worse
outcome. Antipsychotic medications, which are effective for treating positive symptoms,
are generally ineffective for treating negative or cognitive symptoms. We present a 23-
year-old woman showing severe symptoms at her first visit to our department. The
patient’s parents reported that their daughter had experienced several years of
psychosocial decline and putative psychiatric symptoms, but no medical attention had
been previously sought; as such, the diagnosis of schizophrenia with predominantly
negative symptoms was very much delayed. Early onset of schizophrenia, longer duration
of untreated psychosis, and severe negative symptoms, which have limited treatment
options, suggested a poor prognosis. We initiated monotherapy with cariprazine, a novel
antipsychotic that has recently been proven efficacious in treating schizophrenia with
predominantly negative symptoms. This report describes a 52-week cariprazine
treatment regimen and follows the patient’s impressive clinical improvement confirmed
by PANSS and CGI scores, and psychological tests.
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Schizophrenia is a severe, chronic, and heterogeneous mental disorder that often has debilitating
long-term outcomes. Its lifetime prevalence rate is estimated to be approximately 1% worldwide in
the adult population (Lehman et al., 2010). Onset generally occurs in late adolescence or early
adulthood, with an average age of 18 years for men and 25 years for women.1 The term early-onset
schizophrenia (EOS) is used to refer to patients who are diagnosed with the disorder before this age.1http://www.schizophrenia.com/szfacts.htm
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a prevalence approaching 0.5% in those younger than 18 years
(Hafner and Van der Heiden, 1997).
Schizophrenia is accompanied by a distortion of personality
that affects fundamental mental and social functions, making
everyday life extremely difficult for patients. Clinical symptoms
are often classified in three main domains: positive symptoms,
such as hallucinations, delusions, suspiciousness/persecution;
negative symptoms, such as emotional withdrawal, blunted
affect, and passive social withdrawal; and cognitive symptoms,
such as impaired perception, learning, thinking, and memorizing.
EOS may be accompanied by greater symptom severity,
premorbid developmental impairment, ‘soft’ neurological signs
(eg, clumsiness, motor incoordination), and a higher rate of
substance abuse (Hsiao and McClellan, 2008; Clemmensen
et al., 2012; Immonen et al., 2017). Accordingly, diagnosis of
EOS is often difficult and frequently delayed since onset is more
commonly insidious than acute, which makes it difficult to
differentiate EOS from underlying cognitive deficits, premorbid
functional impairment, or other abnormalities (Russell, 1994;
Bartlet, 2014). Given this common delay in recognition of the
disorder, the duration of untreated psychosis is often very long,
further contributing to a poor outcome (Penttila et al., 2014).
Although various hypotheses have been developed, the
etiopathogenesis of schizophrenia and EOS is not fully
understood (McGuffin, 2004; Klosterkotter et al., 2011).2 Among
the rising and falling neurochemical theories, the dopamine
hypothesis has remained a primary hypothesis guiding the
treatment of schizophrenia. There are four dopaminergic
pathways in the human brain: the mesolimbic, the mesocortical,
the tuberoinfundibular, and the nigrostriatal. Positive symptoms of
schizophrenia are associated with the hyperdopaminergic state of
D2 receptors in the mesolimbic area, while negative and cognitive
symptoms are believed to be related to the hypodopaminergic
dysregulation of the prefrontal cortex (Stahl, 2003).
Negative symptoms of schizophrenia, which affect up to 60%
of patients with schizophrenia (Rabinowitz et al., 2013), form a
complex clinical constellation of symptoms that challenge both
diagnosis and treatment. By definition, negative symptoms mean
the absence of normal functions. Negative symptoms are
classified by their etiology as primary negative symptoms,
which are core features of the disease itself, and secondary
negative symptoms, which are consequences of positive
symptoms, ant ipsychotic treatment , depress ion or
extrapyramidal side effects. Five constructs have been accepted
by general consensus as key aspects of negative symptoms:
blunted affect, alogia, anhedonia, asociality, and avolition
(Marder and Galderisi, 2017). Patients with predominant
negative symptoms lose their motivation, cannot function at
school or work, and their interpersonal relationships severely
decay. Due to impaired daily functioning and social amotivation,
they may need constant care.
Although early intervention is associated with improvement
in negative symptoms (Boonstra et al., 2012), this may be
challenging since negative symptoms develop slowly and may2https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml
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(Kirkpatrick et al., 2001; Galderisi et al., 2018). Moreover, a more
insidious onset predicts poorer outcome and more severe
negative symptoms (Kao and Liu, 2010; Immonen et al., 2017;
Murru and Carpiniello, 2018). Diagnosis of patients with
predominantly negative symptoms (lacking manifest psychotic
signs) is often delayed, resulting in a longer duration of untreated
psychosis. The length of untreated psychosis is closely related to
poorer functional outcome (Perkins et al., 2005).
Negative symptoms have traditionally had minimal response
to antipsychotic treatment. First-generation antipsychotics are
effective in treating positive symptoms, but negative symptom
improvement is only evident when symptoms are secondary to
positive symptoms. It was initially hoped that second-generation
antipsychotics would target both positive and negative symptoms,
but efficacy data have been disappointing. This was a large meta-
analysis where only four second-generation drugs (amisulpride,
risperidone, olanzapine, and clozapine) resulted to be more
efficacious than first-generation antipsychotics in the overall
change of symptoms, including positive and negative symptoms.
The other examined second-generation antipsychotics were only
as efficacious as first-generation antipsychotic agents (Leucht
et al., 2009). These studies were mainly conducted in patients
with general symptoms of schizophrenia, therefore a secondary
effect on negative symptoms could not be ruled out. Therefore
negative symptom improvement cannot be considered a core
component of atypicality (Veerman et al., 2017). Previous studies
have demonstrated that no drug had a beneficial effect on negative
symptoms when compared to another drug (Arango et al., 2013;
Millan et al., 2014; Fusar-Poli et al., 2015), meaning that head to
head comparisons of different agents among each other did not
result in superiority of one drug to another. The latest comparison
(Krause et al., 2018) evaluated all studies that have been
performed in the negative symptom population so far, and has
found that amisulpride claimed superiority only to placebo,
olanzapine was superior to haloperidol, but only in a small trial
(n = 35), and cariprazine outperformed risperidone in a large well-
controlled trial.
Hence cariprazine emerged as an agent of particular interest
in regard to negative symptoms. Cariprazine is a dopamine D3/
D2 receptor partial agonist and serotonin 5-HT1A receptor
partial agonist. It has been hypothesized that cariprazine is the
only antipsychotic that can block D3 receptors in the living brain,
thereby exhibiting functions that are related to D3 blockade (e.g.,
improvement of negative symptoms) (Stahl, 2016). In that large
clinical trial including 460 patients with predominant negative
symptoms and stable positive symptoms of schizophrenia,
cariprazine was significantly more effective than risperidone in
improving negative symptoms and patient functioning (Nemeth
et al., 2017).CASE DESCRIPTION
The 23-year-old female patient visited the Institute of Rare
Diseases at our university with her parents. They hadApril 2020 | Volume 11 | Article 477
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daughter, but this was the first time they had asked for medical
help. The patient was quiet and restrained since she did not speak
much, her parents told us her story instead. Initially, the patient
had done very well in a bilingual secondary school and was
socially active with friends and peers. At the age of 15 years, her
academic performance started to deteriorate, with her first
problems associated with difficulty learning languages and
memorizing. Her school grades dropped, and her personality
started to gradually change. She became increasingly irritated,
and was verbally and physically hostile toward her classmates,
resorting to hitting and kicking at times. She was required to
repeat a school year and subsequently dropped out of school at
the age of 18 because she was unable to complete her studies.
During these years, her social activity greatly diminished. She
lived at home with her parents, did not go out with friends, or
participate in relationships. Most of the time she was silent and
unsociable, but occasionally she had fits of laughter without
reason. Once the patient told her mother that she could hear the
thoughts of others and was probably hearing voices as well.
Slowly, her impulse-control problems faded; however,
restlessness of the legs was quite often present.
Our patient’s medical history was generally unremarkable.
She lacked neurological or psychiatric signs. She had a
tonsillectomy and adenotomy at age 7 years. Epilepsy was
identified in the patient’s family history (father’s uncle). On
physical examination, there were no signs of internal or
neurological disease; body mass index was 21.5 (normal weight).
During the first psychiatric interview and examination, we
found that our patient was alert and vigilant, but had trouble
relating due to decreased integrity of consciousness. Her
attention could be aroused or partially directed, and she had
difficulty keeping a target idea. Autopsychic and allopsychic
orientations were preserved. Longer thinking latencies and
slowed movement responses were observed, sometimes with
even cataleptic impressions. Cognitive functions, such as
thinking, memory, and concept formation, were severely
impaired, and we were unable to carry out some of our
neurocognitive tests -such as the Addenbrooke’s Cognitive
Examination (Hsieh et al., 2013), the Toulouse-Pieron
attention test (Kanizsa G1951), Bells test (Gauthier et al., 1989)
and the Trail Making Test- because of the patient’s denial of
symptoms and refusal to cooperate.
She often looked aside and laughed frequently, suggesting the
presence of perceptual disturbances, but she denied her
symptoms when asked. In contrast to the periodic
inappropriate laughing, apathy and anhedonia were markedly
present. During the examination, the patient could not recall
anything she would do or even think of with pleasure. According
to the heteroanamnesis, she lost her interest in activities she used
to like, did not go out with friends anymore, and showed no signs
of joy or intimacy towards her family members either.
Along with the affective hyporesponsiveness, amotivation and
a general psychomotor slowing were observed. Hypobulia, void
perspectives, and lack of motivation were explored. Parental
statements indicated that the patient’s social activity hadFrontiers in Pharmacology | www.frontiersin.org 3continued to diminish, and her appearance and personal
physical hygiene had deteriorated. When we initiated a
conversation, the patient was negativistic and agitated. Her
critical thinking ability was reduced, which led to inappropriate
behavior (she, e.g., unexpectedly stood up and left the room while
the examination was still ongoing). Considering her status, she
was admitted to the clinic after her first visit.
After several differential diagnostic tests were performed (e.g.,
routine diagnostic laboratory parameters, immune serological
analyses, electroencephalogram, magnetic resonance imaging,
genetic testing), all the possible common and rare disorders, such
as Huntington’s disease, Niemann Pick C disease, mitochondrial
disorders, and autoimmune diseases, were ruled out.
At first contact, to differentiate the symptoms and severity of
putative schizophrenia, we mapped the positive, negative, and
general symptoms, as well as a clinical impression, using the
Positive and Negative Syndrome Scale (PANSS), the Scale for
Assessment of Negative Symptoms, and the Clinical Global
Impressions-Severity (CGI-S) (Groth-Marnat, 2009).
The patient had a very high PANSS total score, which
corresponded to being considered “severely ill” or “among the
most severely ill’ on the CGI-S (Leucht et al., 2005). The PANSS
score was derived dominantly from the negative items of the
scale. Overall, her negative symptoms fulfilled criteria for
predominantly negative symptoms, meaning that positive
symptomatology was reduced, while negative symptoms were
more explicit and dominated the clinical picture (Riedel et al.,
2005; Olie et al., 2006; Mucci et al., 2017). Baseline rating scale
sores are presented in Table 1.
The diagnosis of EOS with predominantly negative symptoms
was given and treatment with the antipsychotic agent cariprazine
was initiated. The patient was hospitalized for 2 weeks following
her arrival at the clinic. Cariprazine was started at the dose of 1.5
mg/day and titrated up to 4.5 mg/day over a 2-week period: the
patient received 1.5 mg/day for the first 3 days, 3 mg/day from
day 4 to day 12, and eventually 4.5 mg/day from day 13 onward.
During these 2 weeks, which were spent in hospital, the patient’sTABLE 1 | Summary of symptom scale scores at the time of admission to the
hospital.
Score at first contact/
admission to hospital
Maximum
score possible
PANSS Total Score 150 210
PANSS Positive Subscale
Score
26 49
PANSS Negative Subscale
Score
45 49
PANSS General
Psychopathology Subscale
Score
79 112
PANSS-FSPS 20 42
PANSS-FSNS 46 49
CGI-S 6 7April 2020 | VolumPANSS, Positive and Negative Syndrome Scale; PANSS-FSNS, Positive and Negative
Syndrome Scale factor score for negative symptoms; PANSS-FSPS, Positive and
Negative Syndrome Scale factor score for positive symptoms; CGI-S, Clinical Global
Impressions-Severity Scale.e 11 | Article 477
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psychomotor retardation, poor eye contact, and affective
nonresponsiveness improved; however, delusions and
hallucinatory perceptions did not fade significantly.
Two weeks after discharge, we saw the patient for her first
outpatient visit. Significant clinical improvement was observed.
The patient calmly cooperated during the examination, with no
signs of agitation. She was oriented to time, place, and self,
attention could be drawn and directed, and she was able to keep a
target idea and change the subject. Although according to the
family, perceptual disturbances were still present, laughing with
no reason and looking aside were much less frequent, and
restlessness of the legs had stopped; these symptoms were not
observed during the examination. Psychomotoric negativism had
improved greatly, the patient was more communicative, and she
paid more attention to the activities of family members. The pace
of speech was close to normal: the thinking latencies and slowed
movement responses as observed at admission were not seen
anymore. The patient had adequate reaction time to questions
asked and could focus in the interview. Mild obstipation and
somnolence in the evening were her main complaints. Apart
from some tick-like eye closures, there was no pathological
finding during physical and neurological examination. At this
point, cariprazine was reduced to 3 mg per day.
At her second outpatient visit, which occurred 8 weeks after
treatment initiation, further improvement was observed.
According to her mother, the patient was more active and open
at home. Neurological examination found that the alternating
movements of her fingers were slightly slowed. Cariprazine 3 mg/
day was continued with concomitant anticholinergic medication.
At the third outpatient visit, which occurred 16 weeks after the
first contact, the patient’s overall symptoms, including cognitive
functions, such as memory and abstract thinking, as well as
functions in activities of daily living, had improved remarkably.
She had started to participate in the family’s daily life, even taking
responsibility for some household duties; further, she went to the
hairdresser for the first time in years, a step forward from herFrontiers in Pharmacology | www.frontiersin.org 4previous state of self-neglect. She was probably still having
auditory hallucinations, which she considered natural, and some
extrapyramidal symptom (EPS)-like ruminating movements, like
to-and-fro swinging of her trunk, were observed. She did not look
aside any more and tics were no longer present. Compared with
previous visits overall, she was very relaxed, retained eye contact,
cooperated, and communicated adequately during the interview.
She started to develop insight into her condition, and she told us
that her “thoughts were not healthy.” At the last two visits, the
synkinesis of the arms was reduced.
After 16 weeks of treatment, the patient’s PANSS Negative
Subscale Score and PANSS factor score for negative symptoms
(PANSS-FSNS) score were reduced by 44.44% and 41.31%,
respectively. Recent studies have demonstrated that linking the
percentage improvement of PANSS with CGI-S and
-Improvement (CGI-I) scores shows that a 25–50% reduction
of PANSS scores corresponds to clinically meaningful change
(Correll et al., 2011; Fusar-Poli et al., 2015). In acutely ill patients
with predominantly positive symptoms who are more likely to
respond well to treatment, the 50% cutoff would be a more
clinically meaningful criterion; however, since even slight
improvement might represent a clinically significant effect in a
patient with atypical schizophrenia, the use of 25% cutoff is
justified (Correll et al., 2011; Fusar-Poli et al., 2015).
In this regard, the 44.44% (change from baseline: −20) and
41.31% (change from baseline: −19) improvement demonstrated
on PANSS Negative Symptom subscale and PANSS-FSNS,
respectively, are considered a clearly clinically relevant change.
Beyond the impaired synkinesis and alternating movement of the
arms and fingers, there were no other treatment-related physical
dysfunctions. Change from baseline on the PANSS and CGI
scales are shown over the course of treatment in Table 2.
Since our patient ’s symptoms demonstrated strong
improvement and tolerability was favorable, cariprazine
therapy was continued. Improvement in both negative and
positive symptoms was maintained over the course of
treatment. At her later visits (32 and 52 weeks), PANSS totalTABLE 2 | Summary of symptom scale scores at weeks 16, 32, and 52.
Score at
admission
Score at 16
weeks of
treatment
Percent change from
baseline (change from
baseline)
Score at 32
weeks of
treatment
Percent change from
baseline (change from
baseline)
Score at 52
weeks of
treatment
Percent change from
baseline (change from
baseline)
PANSS
Total
Score
150 92 38.66% (−58) 37 75.33% (−113) 37 75.33% (−113)
PANSS-
PSS
26 14 46.15% (−12) 9 65.38% (−17) 9 65.38% (−17)
PANSS-
NSS
45 25 44.44% (−20) 15 66.67% (−30) 15 66.67% (−30)
PANSS-
FSPS
20 9 55.00% (−11) 6 70.00% (−14) 6 70.00% (−14)
PANSS-
FSNS
46 27 41.31% (−19) 14 69.56% (−32) 14 69.56% (−32)
CGI-S 6 4 NA 2 NA 2 NA
CGI-I NA 2 NA 1 NA 1 NAApril 202PANSS, Positive and Negative Syndrome Scale; PANSS-PSS, PANSS Positive Subscale Score; PANSS-NSS, PANSS Negative Subscale Score; PANSS-FSNS, Positive and Negative
Syndrome Scale factor score for negative symptoms; PANSS-FSPS, Positive and Negative Syndrome Scale factor score for positive symptoms; CGI-S, Clinical Global Impressions-
Severity Scale; CGI-I, Clinical Global Impressions-Improvement Scale. NA indicates not applicable.0 | Volume 11 | Article 477
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the decrease in negative symptom scores was considerable
(PANSS-NSS=66.67% and PANS-FSNS=70.00% at both time
points). The patient’s progress was also reflected in clinical and
functional measurements, with the CGI-S score reduced to 2
(borderline mentally ill) and a CGI-I score of 1 (very much
improved) indicating notable improvement.DISCUSSION
Cariprazine has demonstrated broad spectrum efficacy in the
treatment of positive and negative symptoms of schizophrenia.
In a field where no treatment is available for difficult-to-treat
negative symptoms, this case is unique and may have important
implications for schizophrenia treatment. Despite experiencing
approximately 8 years of untreated symptoms and functional
impairment associated with predominantly negative symptom
EOS, our 23-year-old female patient showed considerable
symptomatic and functional improvement after several weeks of
treatment with cariprazine. Given that the duration of untreated
negative symptoms is associated with worse functional outcomes
(Boonstra et al., 2012), the remarkable improvement seen in this
case shows how valuable cariprazine could be for patients with
similar symptom presentations. Although it is not possible to
generalize the observations and findings of this single case, it has
the novelty of detecting a potential effect of cariprazine in a drug-
naïve patient with marked negative symptoms of early-onset
schizophrenia. To our knowledge, no cariprazine-related data
has been published in this type of patients. A single case study
is obviously far from being predictive for the efficacy of a drug,
however, the results seen with this case are promising.With a dose
recommended for patients with negative symptoms, our patient’s
clinical condition, including positive, negative, and cognitive
symptoms, as well as social functioning have improved notably,
with the effect maintained for over 12 months. Generally,
cariprazine has been well tolerated, with mild EPS observed
after 8 weeks, but no metabolic, cardiac, or other side effects.CONCLUSION
This case report suggests that the management of patients with
EOS and prominent negative symptoms is achievable in everydayFrontiers in Pharmacology | www.frontiersin.org 5practice with cariprazine. More real-world clinical experience is
needed to support this finding.DATA AVAILABILITY STATEMENT
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